[Carlo] Speroni, Italien, marathon [modifié des Jeux interalliés, stade Pershing, le 4 juillet 1919] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54704

[Clinton] Larsen, saut en hauteur [vainqueur des Jeux interalliés avec 1m86, stade Pershing, le 4 juillet 1919] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54703

[Earl William] Eby, Américain, 2ème, [Daniel Leslie] Mason, Nouvelle-Zélande, 1er du 800 [mètres des Jeux interalliés, stade Pershing, le 4 juillet 1919] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54702

[Ahmed] Djebelia, Français [participant au marathon modifié des Jeux interalliés, stade Pershing, le 4 juillet 1919] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54701

[Jean] Vermeulen, Français, [Scarlat] Florea [n° 2192], Roumain [avec le Roumain Alexandru Balan, n° 2195, et le belge Jules Holsbeeke, n° 1274, marathon modifié des Jeux interalliés, stade Pershing, le 4 juillet 1919] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54700

Detection of the pandemic norovirus variant GII.4 Sydney 2012 in Rio Branco, state of Acre, northern Brazil

Noroviruses (NoVs) are important cause of gastroenteritis in humans worldwide. Genotype GII.4 is responsible for the majority of outbreaks reported to date. This study describes, for the first time in Brazil, the circulation of NoV GII.4 variant Sydney 2012 in faecal samples collected from children aged less than or equal to eight years in Rio Branco, state of Acre, northern Brazil, during July-September 2012.

4-7-19, stade Pershing, escrime [Jeux interalliés] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54708

4-7-19, stade Pershing, saut [en] hauteur avec élan [Robert Lyman "Dink" Templeton sautant, et Carl Rice en attente à gauche de l'aire de saut, Jeux interalliés] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54707

Megazol and its bioisostere 4H-1,2,4-triazole: comparing the trypanocidal, cytotoxic and genotoxic activities and their in vitro and in silico interactions with the Trypanosoma brucei nitroreductase enzyme

Megazol (7) is a 5-nitroimidazole that is highly active against Trypanosoma cruzi and Trypanosoma brucei, as well as drug-resistant forms of trypanosomiasis. Compound 7 is not used clinically due to its mutagenic and genotoxic properties, but has been largely used as a lead compound. Here, we compared the activity of 7 with its 4H-1,2,4-triazole bioisostere (8) in bloodstream forms of T. brucei and T. cruzi and evaluated their activation by T. brucei type I nitroreductase (TbNTR) enzyme. We also analysed the cytotoxic and genotoxic effects of these compounds in whole human blood using Comet and fluorescein diacetate/ethidium bromide assays. Although the only difference between 7 and 8 is the substitution of sulphur (in the thiadiazole in 7) for nitrogen (in the triazole in 8), the results indicated that 8 had poorer antiparasitic activity than 7 and was not genotoxic, whereas 7 presented this effect. The determination of Vmax indicated that although 8 was metabolised more rapidly than 7, it bounds to the TbNTR with better affinity, resulting in equivalent kcat/KM values. Docking assays of 7 and 8 performed within the active site of a homology model of the TbNTR indicating that 8 had greater affinity than 7.

Evaluación económica de la monoterapia con tocilizumab frente a adalimumab en artritis reumatoide.

BACKGROUND Tocilizumab (TCZ) was superior to adalimumab (ADA), as monotherapy, in reducing signs and symptoms of adult rheumatoid arthritis (RA) when methotrexate (MTX) treatment is poorly tolerated or inappropriate. The aim of the study was to analyze the cost-effectiveness of TCZ vs ADA in these patients. METHODS Economic evaluation of the cost per response or remission of TCZ vs ADA from ADACTA (time horizon: 24 weeks). Clinical response criteria ACR or disease remission criteria, DAS28. PERSPECTIVE National Health System. The costs included (acquisition, administration and monitoring of medicines; € 2012) were obtained from Spanish sources. Simple univariate sensitivity analyzes were performed. RESULTS ACR20, ACR50 and ACR70 response rates with TCZ and ADA were obtained in 65% and 49.4% (p <0.01), 47.2% and 27.8% (p <0.01); and 32.5% and 17.9% (p <0.01) of patients, respectively. DAS28 remission occurred in 39.9% and 10.5%, respectively (p <0.0001). The cost per response was lower with TCZ than with ADA (ACR20: € 8,105 and € 11,553; ACR50: € 11,162 and € 20,529; ACR70: € 16,211 and € 31,882) respectively. The cost of DAS28 remission was € 13,204 and € 54,352, respectively. Treatment with TCZ was dominant (more effective, with lower costs vs ADA) in all scenarios analyzed. CONCLUSIONS According to this analysis, in Spain TCZ monotherapy is an efficient strategy vs ADA for treating RA patients intolerant to MTX or in which there is inappropriate response.

Registro de fallos en accesos a caché (L2) del Pentium 4 mediante performance counters

Nuestro proyecto intentará conseguir la contabilización de los fallos en los accesos a caché de segundo nivel (L2) de un determinado proceso, para lo que trataremos de habilitar los contadores de rendimiento del Pentium 4, configurarlos para obtener la información buscada de acuerdo a los eventos a monitorizar y, por último, obtener esta información y dejarla adisposición de la aplicación de usuario que la requiera.